Loading stock data…
Alvotech (ALVO)
$3.68+0.20 (+5.75%)
Pre-Market$3.71+0.03 (+0.82%)· Last close Jun 26
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alvotech in the Healthcare sector is trading at $3.68 with a market capitalization of $1.3B. Wall Street consensus targets $13.83 (6 analysts), implying a +275.9% move over the next 12 months. The stock is currently near its 52-week low of $2.94, remaining 27.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +275.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $166.57M↑ | $113.74M↓ | $173.24M↑ | $132.76M↓ | $151.21M |
| Gross Profit | $105.29M↑ | $78.74M↓ | $99.41M↑ | $67.32M↓ | $70.88M |
| Operating Income | $48.26M↑ | $1.31M↓ | $18.06M↑ | $10.58M↓ | $13.47M |
| Net Income | -$108.55M↓ | -$5.25M↓ | $32.04M↓ | $109.68M↑ | -$66.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.60%
Volume
Today's trading volume
991,865
Recent News
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential
Alvotech (NASDAQ:ALVO) is one of the penny stocks with explosive growth potential. On June 18, Alvotech closed its underwritten public offering of 26,066,667 ordinary shares at $3.75 per share, raising ~$98 million in gross proceeds. This figure includes the full exercise of the underwriters’ option to purchase additional shares. The offering is complemented by a […]
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Fed Policy Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.04%, and the actively tr
Alvotech Prices Share Offering, Private Placement
Alvotech (ALVO) has priced an underwritten public offering of about 22.7 million shares at $3.75 per
Alvotech Launches Public Offering, Private Placement of Ordinary Shares
Alvotech (ALVO) said late Monday it has commenced an underwritten public offering of its ordinary sh
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through regulatory review and prepares for a broader launch cycle over the next several years. Speaking dur